{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:14:23Z","timestamp":1773112463819,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In Quebec, 1 dose of monovalent C meningococcal conjugate vaccine (Men-C-Con) is offered at 12 months of age and a booster dose in grade 9 (14\u201315 years of age). In other Canadian provinces, a quadrivalent vaccine against serogroups ACWY (Men-4-Con) is increasingly used for adolescents. An economic analysis was performed to assess the value of a switch from Men-C-Con to Men-4-Con.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A compartmental static simulation model was developed to assess the burden of invasive meningococcal disease due to serogroups AWY (AWY-IMD) in a cohort of 100,000 persons with different vaccination programs. Univariate and multivariate sensitivity analyses were performed, including variation in vaccine price difference ($12; range: $0\u2013$20), AWY-IMD rate (0.08\/100,000 to 0.28\/100,000 person-years), level of herd immunity generated by adolescent vaccination (from zero to disease elimination) and discounting rate (0%, 3% or 6%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In the low AWY-IMD rate base scenario, replacing Men-C-Con by Men-4-Con for adolescents would reduce disease burden by 16% (no herd effect) to 58% (moderate herd effect), with an incremental cost-effectiveness ratios between $445,000 per quality-adjusted life-year (QALY) and $167,000\/QALY in a societal perspective. In the high AWY-IMD rate scenario, incremental cost-effectiveness ratio would be in the range of $97,000\/QALY to $19,000\/QALY.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Based on the epidemiologic conditions in Quebec and in most other Canadian provinces, the benefits of Men-4-Con in reducing the burden of disease would be low for a high cost. The switch would, however, be more economically attractive with a much higher incidence rate (as in a few provinces) or with a reduced vaccine price in conditions assuming a moderate to high herd effect.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001512","type":"journal-article","created":{"date-parts":[[2016,12,25]],"date-time":"2016-12-25T16:59:02Z","timestamp":1482685142000},"page":"e203-e207","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada"],"prefix":"10.1097","volume":"36","author":[{"given":"Philippe","family":"De Wals","sequence":"first","affiliation":[{"name":"Institut national de Sant\u00e9 publique du Qu\u00e9bec, Quebec City, Qu\u00e9bec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institut national de Sant\u00e9 publique du Qu\u00e9bec, Quebec City, Qu\u00e9bec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.vaccine.2003.09.022","article-title":"Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease.","volume":"22","author":"De Wals","year":"2004","journal-title":"Vaccine"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","article-title":"Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.","volume":"25","author":"De Wals","year":"2007","journal-title":"Vaccine"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO Guide for standardisation of economic evaluations of immunization programmes.","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40272-016-0169-1","article-title":"What would be the best schedule for prevention of meningococcal disease in all ages? The UK experience.","volume":"18","author":"Findlow","year":"2016","journal-title":"Paediatr Drugs"},{"key":"R12-20230912","first-page":"1","article-title":"An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS).","volume":"35","year":"2009","journal-title":"Can Commun Dis Rep"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1086\/520303","article-title":"Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.","volume":"26","author":"Erickson","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1155\/2007\/713576","article-title":"The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.","volume":"18","author":"Morrow","year":"2007","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11136-008-9354-1","article-title":"Evidence on the construct validity of the Health Utilities Index Mark 2 and Mark 3 in patients with chronic kidney disease.","volume":"17","author":"Davison","year":"2008","journal-title":"Qual Life Res"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0749-3797(02)00462-2","article-title":"Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis.","volume":"23","author":"Scott","year":"2002","journal-title":"Am J Prev Med"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/S0264-410X(02)00161-5","article-title":"Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.","volume":"20","author":"De Wals","year":"2002","journal-title":"Vaccine"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1001\/jama.284.7.850","article-title":"Cost-utility analysis of the cochlear implant in children.","volume":"284","author":"Cheng","year":"2000","journal-title":"JAMA"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1542\/peds.2010-0796","article-title":"Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.","volume":"128","author":"Greer","year":"2011","journal-title":"Pediatrics"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R24-20230912","article-title":"Update on the use of quadrivalent conjugate meningococcal vaccines.","volume":"39","year":"2013","journal-title":"Can Commun Dis Rep"},{"issue":"suppl 2","key":"R25-20230912","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","article-title":"The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations.","volume":"33","author":"S\u00e1fadi","year":"2015","journal-title":"Vaccine"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12879-014-0663-4","article-title":"Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.","volume":"14","author":"Kristiansen","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"suppl 5","key":"R29-20230912","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1093\/cid\/civ597","article-title":"Meningococcal meningitis surveillance in the African meningitis belt, 2004\u20132013.","volume":"61","author":"Lingani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R32-20230912","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vaccine.2013.09.034","article-title":"Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.","volume":"33","author":"Vickers","year":"2015","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R33-20230912","doi-asserted-by":"crossref","first-page":"B29","DOI":"10.1016\/j.vaccine.2015.03.023","article-title":"Valuing vaccines: deficiencies and remedies.","volume":"33","author":"Bloom","year":"2015","journal-title":"Vaccine"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.vaccine.2004.10.029","article-title":"An analytical framework for immunization programs in Canada.","volume":"23","author":"Erickson","year":"2005","journal-title":"Vaccine"},{"key":"R35-20230912","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(13)61572-X","article-title":"The price of prevention: what now for immunisation against meningococcus B?","volume":"382","author":"Moxon","year":"2013","journal-title":"Lancet"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201707000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:05:07Z","timestamp":1694556307000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201707000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001512","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}